Theralase Technologies Inc. Total Liabilities
Theralase Technologies Inc. total liabilities. Based on the latest financial reports, Theralase Technologies Inc. (TLT) has total liabilities worth CA$1.28 Million CAD (≈ $928.76K USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Theralase Technologies Inc.'s assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Theralase Technologies Inc. (2001–2025)
Total liabilities of Theralase Technologies Inc. from 2001 to 2025. This chart illustrates how Theralase Technologies Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Theralase Technologies Inc. Competitors by Total Liabilities
The table below lists competitors of Theralase Technologies Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Poongwon Precision Co. Ltd.
KQ:371950
|
Korea | ₩69.54 Billion |
|
Namyang Dairy Products Co Ltd Peffered Series 1
KO:003925
|
Korea | ₩146.42 Billion |
|
Stalprofil S.A.
WAR:STF
|
Poland | zł613.12 Million |
|
De Nora India Limited
NSE:DENORA
|
India | Rs479.57 Million |
|
Namib Minerals Ordinary Shares
NASDAQ:NAMM
|
USA | $102.07 Million |
|
HS Valve Co. Ltd
KQ:039610
|
Korea | ₩37.23 Billion |
|
Feerum S.A.
WAR:FEE
|
Poland | zł42.23 Million |
|
Histeel
KO:071090
|
Korea | ₩148.77 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Theralase Technologies Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Theralase Technologies Inc..
Liquidity & Leverage Metrics
Theralase Technologies Inc. Total Liabilities Ratios Explained
Theralase Technologies Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Theralase Technologies Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Theralase Technologies Inc. (2001–2025)
The table below shows the annual total liabilities of Theralase Technologies Inc. from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$1.72 Million ≈ $1.24 Million |
+45.55% |
| 2024-12-31 | CA$1.18 Million ≈ $853.23K |
-13.99% |
| 2023-12-31 | CA$1.37 Million ≈ $992.02K |
+28.36% |
| 2022-12-31 | CA$1.07 Million ≈ $772.82K |
+22.12% |
| 2021-12-31 | CA$874.79K ≈ $632.81K |
+2.06% |
| 2020-12-31 | CA$857.13K ≈ $620.04K |
-46.92% |
| 2019-12-31 | CA$1.61 Million ≈ $1.17 Million |
-37.07% |
| 2018-12-31 | CA$2.57 Million ≈ $1.86 Million |
+100.90% |
| 2017-12-31 | CA$1.28 Million ≈ $923.86K |
+132.32% |
| 2016-12-31 | CA$549.74K ≈ $397.67K |
-30.03% |
| 2015-12-31 | CA$785.66K ≈ $568.34K |
+53.52% |
| 2014-12-31 | CA$511.75K ≈ $370.19K |
-44.43% |
| 2013-12-31 | CA$920.99K ≈ $666.23K |
-23.08% |
| 2012-12-31 | CA$1.20 Million ≈ $866.17K |
+25.29% |
| 2011-12-31 | CA$955.71K ≈ $691.35K |
+35.30% |
| 2010-12-31 | CA$706.35K ≈ $510.97K |
+0.35% |
| 2009-12-31 | CA$703.90K ≈ $509.19K |
-11.44% |
| 2008-12-31 | CA$794.79K ≈ $574.94K |
+137.16% |
| 2007-12-31 | CA$335.12K ≈ $242.42K |
+6.81% |
| 2006-12-31 | CA$313.74K ≈ $226.96K |
+97.34% |
| 2005-12-31 | CA$158.99K ≈ $115.01K |
-1.57% |
| 2004-12-31 | CA$161.52K ≈ $116.84K |
-25.13% |
| 2003-12-31 | CA$215.75K ≈ $156.07K |
+1912.38% |
| 2002-12-31 | CA$10.72K ≈ $7.76K |
+12.16% |
| 2001-12-31 | CA$9.56K ≈ $6.91K |
-- |
About Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form … Read more